about
Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patientsInitial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing programClinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activityThe interplay of reovirus with autophagyTrial Watch:: Oncolytic viruses for cancer therapyModification of mammalian reoviruses for use as oncolytic agentsA novel classification of lung cancer into molecular subtypesIsolation of reovirus T3D mutants capable of infecting human tumor cells independent of junction adhesion molecule-A.A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium reportProteolytic disassembly of viral outer capsid proteins is crucial for reovirus-mediated type-I interferon induction in both reovirus-susceptible and reovirus-refractory tumor cells.The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer.Reovirus variants with mutations in genome segments S1 and L2 exhibit enhanced virion infectivity and superior oncolysis.Trial watch: Oncolytic viruses for cancer therapyReolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer.A classical PKA inhibitor increases the oncolytic effect of M1 virus via activation of exchange protein directly activated by cAMP 1.Pancreatic cancer gene therapy: from molecular targets to delivery systems.Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy.Activated ras signaling pathways and reovirus oncolysis: an update on the mechanism of preferential reovirus replication in cancer cells.Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus.The oncolytic virus, pelareorep, as a novel anticancer agent: a review.Oncolytic Immunotherapy for Treatment of Cancer.Oncolytic virus-initiated protective immunity against prostate cancerAn improved reverse genetics system for mammalian orthoreovirusesREO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors.Bio-distribution study of Reolysin® (pelareorep) through a single intravenous infusion in Sprague-Dawley rats.Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma.Model-based rational design of an oncolytic virus with improved therapeutic potential.Oncolytic reovirus inhibits angiogenesis through induction of CXCL10/IP-10 and abrogation of HIF activity in soft tissue sarcomas.Anti-tumor efficacy of oncolytic reovirus against gastrointestinal stromal tumor cells.
P2860
Q24617027-3B844BCF-C429-41AE-8E0F-3ACB8EF699ADQ24627862-F619C7C5-3A29-4C75-8362-941F5FC678C7Q26750568-AAEE1238-8C1C-4D6A-90BD-8B53A3CDCE02Q26851826-C427F6E6-4F5B-4B9A-9E62-D6D09B6013FDQ27021951-8D9AA2E7-B74F-4455-86CF-309EDEAF71D1Q28264900-C5A91D39-9208-4DE3-83AF-1CF3F9559BA3Q28731874-5E6AC714-4975-4E5C-BEE7-7FCC71A4F92DQ34460916-A63EF4CA-3BD4-4D48-A86E-E8906A93CB08Q35224368-5CCA6DA4-01EB-4882-A83B-6DBCEF51FA04Q35249529-EFFBF74C-0B19-4AAD-ACC7-3969B9D8ED8AQ35686522-946E8927-8F24-4801-8FE1-CDE243AE27B7Q36155535-2CC4B88A-B8AB-488B-A1B3-C884FD07602AQ37028023-9E098CF4-980D-440A-9D7B-C9C747F77BDCQ37062074-EB8FC959-2D03-483B-9CA5-13BA3CCD52BAQ37565501-899D98B4-AFB3-47B5-B14F-8ABD759EF9B6Q38161331-04FC2597-53E8-4E50-BAD1-31C96233A32CQ38194135-7354E006-76AB-4135-99E0-2F9D8BD7A2D7Q38229052-E7A62670-FE84-4A27-A775-DE90F58EECDFQ38315523-83552F9F-E652-4875-8148-53D6B1672385Q38360781-BE51BEA8-3306-47A7-A117-74C080B3523FQ38848223-4006091F-5F0D-418B-9FE9-2E015FBD5694Q39606073-70BBA8C5-1DD4-4826-8FA3-34BDCAEF1E55Q39757270-D6AAF6A1-C877-4E16-B2AF-5AE6758C8C51Q41410427-B2F9771A-E40F-48BE-805B-86A209E47209Q42262762-289FE652-21C7-4846-AE0E-1960F2CB9CE3Q44623962-A7EAA2EA-5107-45AB-A098-3F8439BC55ECQ45350759-AA071433-EFD3-4975-AF11-C29C1A81E086Q47266341-4015B6AB-269B-4019-8CC9-66824B644F5AQ49569173-D1FBBD3C-812F-4480-926A-5074B8B3E283
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Reovirus-based therapy for cancer.
@en
Reovirus-based therapy for cancer.
@nl
type
label
Reovirus-based therapy for cancer.
@en
Reovirus-based therapy for cancer.
@nl
prefLabel
Reovirus-based therapy for cancer.
@en
Reovirus-based therapy for cancer.
@nl
P2093
P2860
P1476
Reovirus-based therapy for cancer.
@en
P2093
Alain Mita
Francis J Giles
Kevin Kelly
Matthew Coffey
Monica Mita
Steffan Nawrocki
P2860
P304
P356
10.1517/14712590903002039
P407
P577
2009-07-01T00:00:00Z